Clinical trial · Observational
Entia Liberty: Capillary Validation
Entia Liberty: Clinical Performance Validation - Capillary Performance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a clinical performance validation study to evaluate the performance of the Entia Liberty device. Patients undergoing routine venepuncture blood tests will be recruited to have an Entia Liberty test (by finger-prick) done on them by a trained healthcare professional. The results from that finger-prick test will be compared against the results from the routine venepuncture blood test (reference method) and subsequently, excess blood from the routine venepuncture test will be run on another Entia Liberty device in the laboratory. All three results (Entia Liberty capillary, Entia Liberty venous and gold standard venous) will be compared against each other to prove Entia Liberty's performance claims.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Entia Liberty | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- To obtain/validate the value of the total error of the Entia Liberty device.
- timeFrame
- 3 months
- description
- The dataset from this study will provide evidence to support the device's performance claims.
- measure
- To obtain/validate the value of the linearity of the Entia Liberty device.
- timeFrame
- 3 months
- description
- The dataset from this study will provide evidence to support the device's performance claims.
- measure
- To obtain/validate the value of the bias of the Entia Liberty device.
- timeFrame
- 3 months
- description
- The dataset from this study will provide evidence to support the device's performance claims.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>18 years old at the time of study entry * Currently receiving standard of care systemic anti- cancer therapy (chemotherapy, immunotherapy, endocrine and targeted therapy) for solid organ malignancy and has received at least one cycle. * Scheduled to be undergoing routine venous laboratory blood tests as part of standard of care * Can provide written informed consent * Blood samples collected and stored in K2-EDTA vacutainers only Exclusion Criteria: * Known inherited or acquired bleeding disorder * History of haematological malignancy * Known poorly controlled anti-coagulation * Inadequate use and understanding of the English language, requiring a translator
References
Publications (0)
Data not yet available